| Year |
Citation |
Score |
| 2024 |
Snacel-Fazy E, Soubéran A, Grange M, Joseph K, Colin C, Morando P, Luche H, Pagano A, Brustlein S, Debarbieux F, Toutain S, Siret C, van de Pavert SA, Rougon G, Figarella-Branger D, ... ... Tchoghandjian A, et al. SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment. Cell Death & Disease. 15: 676. PMID 39278921 DOI: 10.1038/s41419-024-07056-z |
0.709 |
|
| 2024 |
Soubéran A, Jiguet-Jiglaire C, Toutain S, Morando P, Baeza-Kallee N, Appay R, Boucard C, Graillon T, Meyer M, Farah K, Figarella-Branger D, Tabouret E, Tchoghandjian A. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible and easy-to-use personalized models. Neuro-Oncology. PMID 39252580 DOI: 10.1093/neuonc/noae184 |
0.447 |
|
| 2024 |
Hein V, Baeza-Kallee N, Bertucci A, Colin C, Tchoghandjian A, Figarella-Branger D, Tabouret E. GD3 ganglioside is a promising therapeutic target for glioma patients. Neuro-Oncology Advances. 6: vdae038. PMID 38590763 DOI: 10.1093/noajnl/vdae038 |
0.786 |
|
| 2023 |
Baeza-Kallee N, Bergès R, Hein V, Cabaret S, Garcia J, Gros A, Tabouret E, Tchoghandjian A, Colin C, Figarella-Branger D. Deciphering the Action of Neuraminidase in Glioblastoma Models. International Journal of Molecular Sciences. 24. PMID 37511403 DOI: 10.3390/ijms241411645 |
0.787 |
|
| 2023 |
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Tchoghandjian A, et al. Challenges in glioblastoma research: focus on the tumor microenvironment: (Trends in Cancer, 9:1 p:9-27, 2023). Trends in Cancer. PMID 36997420 DOI: 10.1016/j.trecan.2023.02.006 |
0.655 |
|
| 2022 |
Bikfalvi A, da Costa CA, Avril T, Barnier JV, Bauchet L, Brisson L, Cartron PF, Castel H, Chevet E, Chneiweiss H, Clavreul A, Constantin B, Coronas V, Daubon T, Dontenwill M, ... ... Tchoghandjian A, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends in Cancer. PMID 36400694 DOI: 10.1016/j.trecan.2022.09.005 |
0.696 |
|
| 2022 |
Figarella-Branger D, Colin C, Baeza-Kallee N, Tchoghandjian A. A2B5 Expression in Central Nervous System and Gliomas. International Journal of Molecular Sciences. 23. PMID 35563061 DOI: 10.3390/ijms23094670 |
0.754 |
|
| 2021 |
Pagano A, Breuzard G, Parat F, Tchoghandjian A, Figarella-Branger D, De Bessa TC, Garrouste F, Douence A, Barbier P, Kovacic H. Tau Regulates Glioblastoma Progression, 3D Cell Organization, Growth and Migration via the PI3K-AKT Axis. Cancers. 13. PMID 34830972 DOI: 10.3390/cancers13225818 |
0.476 |
|
| 2020 |
Soubéran A, Tchoghandjian A. Practical Review on Preclinical Human Glioblastoma Models: Advances and Challenges for Clinical Translation. Cancers. 12. PMID 32825103 DOI: 10.3390/Cancers12092347 |
0.411 |
|
| 2020 |
Bergès R, Tchoghandjian A, Sergé A, Honoré S, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis. Oncotarget. 11: 759-774. PMID 32165998 DOI: 10.18632/Oncotarget.27374 |
0.638 |
|
| 2019 |
Soubéran A, Brustlein S, Gouarné C, Chasson L, Tchoghandjian A, Malissen M, Rougon G. Effects of VEGF blockade on the dynamics of the inflammatory landscape in glioblastoma-bearing mice. Journal of Neuroinflammation. 16: 191. PMID 31660979 DOI: 10.1186/S12974-019-1563-8 |
0.7 |
|
| 2019 |
Baeza-Kallee N, Bergès R, Soubéran A, Colin C, Denicolaï E, Appay R, Tchoghandjian A, Figarella-Branger D. Glycolipids Recognized by A2B5 Antibody Promote Proliferation, Migration, and Clonogenicity in Glioblastoma Cells. Cancers. 11. PMID 31466399 DOI: 10.3390/Cancers11091267 |
0.805 |
|
| 2019 |
Soubéran A, Cappaï J, Chocry M, Nuccio C, Raujol J, Colin C, Lafitte D, Kovacic H, Quillien V, Baeza-Kallee N, Rougon G, Figarella-Branger D, Tchoghandjian A. Inhibitor of Apoptosis Proteins Determine Glioblastoma Stem-Like Cells Fate in an Oxygen-Dependent Manner. Stem Cells (Dayton, Ohio). PMID 30920104 DOI: 10.1002/Stem.2997 |
0.791 |
|
| 2019 |
Chanez B, Appay R, Guille A, Lagarde A, Adelaide J, Denicolai E, Campello C, Tchoghandjian A, Petrirena G, Colin C, Barrie M, Baeza-Kallee N, Boucard C, Jiguet-Jiglaire C, Graillon T, et al. Genomic analysis of paired IDHwt glioblastoma (GB) to reveal recurrent alterations of MPDZ at relapse after radiotherapy and temozolomide (RTCT). Journal of Clinical Oncology. 37: e13535-e13535. DOI: 10.1200/Jco.2019.37.15_Suppl.E13535 |
0.788 |
|
| 2019 |
Berges R, Tchoghandjian A, Serge A, Honore S, Figarella-Branger D, Bachmann F, Lane H, Braguer D. P11.31 EB1-dependent survival of glioblastoma tumor-bearing mice after treatment with the novel checkpoint activator BAL101553 is associated with inhibition of cancer stem-like cell-mediated tumor angiogenesis and astrocytic differentiation Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz126.177 |
0.624 |
|
| 2018 |
Berges R, Denicolai E, Tchoghandjian A, Baeza-Kallee N, Honore S, Figarella-Branger D, Braguer D. Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma. Cell Death & Disease. 9: 984. PMID 30250248 DOI: 10.1038/S41419-018-1018-7 |
0.814 |
|
| 2016 |
Berges R, Tchoghandjian A, Honore S, Esteve MA, Figarella-Branger D, Bachmann F, Lane HA, Braguer D. The novel tubulin-binding, checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells. Molecular Cancer Therapeutics. PMID 27540016 DOI: 10.1158/1535-7163.Mct-16-0252 |
0.67 |
|
| 2016 |
Tchoghandjian A, Soubéran A, Tabouret E, Colin C, Denicolaï E, Jiguet-Jiglaire C, El-Battari A, Villard C, Baeza-Kallee N, Figarella-Branger D. Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. Cell Death & Disease. 7: e2325. PMID 27490930 DOI: 10.1038/Cddis.2016.214 |
0.771 |
|
| 2016 |
Ricard C, Tchoghandjian A, Luche H, Grenot P, Figarella-Branger D, Rougon G, Malissen M, Debarbieux F. Phenotypic dynamics of microglial and monocyte-derived cells in glioblastoma-bearing mice. Scientific Reports. 6: 26381. PMID 27193333 DOI: 10.1038/Srep26381 |
0.76 |
|
| 2016 |
Tchoghandjian A, Koh MY, Taieb D, Ganaha S, Powis G, Bialecki E, Graziani N, Figarella-Branger D, Metellus P. Hypoxia-associated factor expression in low-grade and anaplastic gliomas: a marker of poor outcome. Oncotarget. PMID 26989023 DOI: 10.18632/Oncotarget.8046 |
0.61 |
|
| 2016 |
Denicolaï E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Meyronet D, Baeza-Kallee N, Chinot O, Figarella-Branger D. Molecular heterogeneity of glioblastomas: does location matter? Oncotarget. 7: 902-13. PMID 26637806 DOI: 10.18632/Oncotarget.6433 |
0.788 |
|
| 2015 |
Taïeb D, Barlier A, Yang C, Pertuit M, Tchoghandjian A, Rochette C, Zattara-Canoni H, Figarella-Branger D, Zhuang Z, Pacak K, Metellus P. Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas. Journal of Neuro-Oncology. PMID 26514359 DOI: 10.1007/S11060-015-1983-Y |
0.469 |
|
| 2015 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Graillon T, Boucard C, Nanni I, Padovani L, Ouafik L, Figarella-Branger D, Chinot O. Recurrence of glioblastoma after radio-chemotherapy is associated with an angiogenic switch to the CXCL12-CXCR4 pathway. Oncotarget. 6: 11664-75. PMID 25860928 DOI: 10.18632/Oncotarget.3256 |
0.791 |
|
| 2015 |
Denicolai E, Tabouret E, Colin C, Metellus P, Nanni I, Boucard C, Tchoghandjian A, Baeza-Kallee N, Fina F, Chinot OL, Figarella-Branger D. Differential molecular expression profile according to glioblastoma (GB) location. Journal of Clinical Oncology. 33: 2030-2030. DOI: 10.1200/Jco.2015.33.15_Suppl.2030 |
0.761 |
|
| 2015 |
Berges R, Tchoghandjian A, Honore S, Figarella-Branger D, Bachmann F, Lane H, Braguer D. Abstract A183: The novel tubulin-binding ‘tumor checkpoint controller’ BAL101553 exerts EB1 expression-dependent antitumor effects on glioblastoma stem-like cells in vitro and in vivo Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A183 |
0.643 |
|
| 2014 |
Denicolaï E, Baeza-Kallee N, Tchoghandjian A, Carré M, Colin C, Jiglaire CJ, Mercurio S, Beclin C, Figarella-Branger D. Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. Oncotarget. 5: 10934-48. PMID 25400117 DOI: 10.18632/Oncotarget.2541 |
0.784 |
|
| 2014 |
Tchoghandjian A, Jennewein C, Eckhardt I, Momma S, Figarella-Branger D, Fulda S. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB. Cell Death and Differentiation. 21: 735-47. PMID 24488095 DOI: 10.1055/S-0034-1393946 |
0.463 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot OL. Expression profile of angiogenic factors in paired initial and recurrent glioblastoma. Journal of Clinical Oncology. 32: 2060-2060. DOI: 10.1200/Jco.2014.32.15_Suppl.2060 |
0.75 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Padovani L, Nanni I, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. AI-29 * ANGIOGENIC SWITCH FROM VEGFR2/HIF1 IN NEWLY DIAGNOSED GLIOBLASTOMA (GB) TO CXCR4-SDF1 PATHWAY IN RECURRENT PAIRED TUMOR AFTER RADIOTHERAPY (RT)-TEMOZOLOMIDE (TMZ) Neuro-Oncology. 16: v7-v7. DOI: 10.1093/Neuonc/Nou238.29 |
0.791 |
|
| 2014 |
Tabouret E, Tchoghandjian A, Denicolai E, Delfino C, Metellus P, Barrie M, Boucard C, Ouafik L, Figarella-Branger D, Chinot O. P04.07 * EXPRESSION PROFILE OF ANGIOGENIC FACTORS IN PAIRED INITIAL AND RECURRENT GLIOBLASTOMA Neuro-Oncology. 16: ii38-ii38. DOI: 10.1093/Neuonc/Nou174.139 |
0.689 |
|
| 2013 |
Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, Lambert S, Baeza-Kallee N, Fernandez C, Chappé C, André N, Figarella-Branger D. Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathologica Communications. 1: 17. PMID 24252689 DOI: 10.1186/2051-5960-1-17 |
0.761 |
|
| 2012 |
Tchoghandjian A, Baeza-Kallee N, Beclin C, Metellus P, Colin C, Ducray F, Adélaïde J, Rougon G, Figarella-Branger D. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties. Annals of Surgical Oncology. 19: S608-19. PMID 21989663 DOI: 10.1245/S10434-011-2093-5 |
0.807 |
|
| 2010 |
Kraus JL, Conti F, Madonna S, Tchoghandjian A, Beclin C. Alternative responses of primary tumor cells and glioblastoma cell lines to N,N-bis-(8-hydroxyquinoline-5-yl methyl)-benzyl substituted amines: cell death versus P53-independent senescence. International Journal of Oncology. 37: 1463-70. PMID 21042714 DOI: 10.3892/Ijo_00000798 |
0.455 |
|
| 2010 |
Figarella-Branger D, Colin C, Tchoghandjian A, Baeza N, Bouvier C. [Glioblastomas: gliomagenesis, genetics, angiogenesis, and microenvironment]. Neuro-Chirurgie. 56: 441-8. PMID 20817192 DOI: 10.1016/J.Neuchi.2010.07.010 |
0.751 |
|
| 2010 |
Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, Ouafik L, Figarella-Branger D. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathology (Zurich, Switzerland). 20: 211-21. PMID 19243384 DOI: 10.1111/J.1750-3639.2009.00269.X |
0.727 |
|
| 2009 |
Tchoghandjian A, Fernandez C, Colin C, El Ayachi I, Voutsinos-Porche B, Fina F, Scavarda D, Piercecchi-Marti MD, Intagliata D, Ouafik L, Fraslon-Vanhulle C, Figarella-Branger D. Pilocytic astrocytoma of the optic pathway: a tumour deriving from radial glia cells with a specific gene signature. Brain : a Journal of Neurology. 132: 1523-35. PMID 19336457 DOI: 10.1093/Brain/Awp048 |
0.791 |
|
| 2007 |
Colin C, Virard I, Baeza N, Tchoghandjian A, Fernandez C, Bouvier C, Calisti A, Tong S, Durbec P, Figarella-Branger D. Relevance of combinatorial profiles of intermediate filaments and transcription factors for glioma histogenesis. Neuropathology and Applied Neurobiology. 33: 431-9. PMID 17442061 DOI: 10.1111/J.1365-2990.2007.00829.X |
0.791 |
|
| Show low-probability matches. |